A SIMPLE KEY FOR ABBV-744 FOR TARGETED CANCER THERAPY TREATMENT UNVEILED

In Segment A, contributors will receive various doses and schedules of oral ABBV-744 pill to discover Risk-free dosing regimen. Extra contributors are going to be enrolled on the identified monotherapy dosign program. In Segment B, contributors will get oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C, members